Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 73-4460 Queen Kaahumanu Hwy, Suite #102 KAILUA KONA HI 96740 |
Tel: | 1-310-3466131 |
Website: | https://www.cyanotech.com |
IR: | See website |
Key People | ||
Matthew K. Custer President, Chief Executive Officer, Director | Felicia Ladin Chief Financial Officer, Vice President of Finance and Administration, Treasurer | Gerald R. Cysewski Chief Executive Officer Emeritus, Chief Scientific Officer |
Glenn D. Jensen Vice President - Operations | Charles J. Hartmann Vice President of Sales and Marketing | Amy B. Nordin Vice President of Human Resources, Secretary | Jennifer M. Johansen Vice President - Quality, Regulatory and Government Affairs |
Business Overview |
Cyanotech Corporation is an agricultural company. It is engaged in the production of natural products derived from microalgae grown in complex and intricate agricultural systems on the Kona coast of Hawaii. It cultivates, on a large-scale basis, two microalgal species from which its two major product lines, natural astaxanthin products and spirulina products, are derived. Its products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye, joint and immune health. BioAstin Hawaiian Astaxanthin has expanding applications as a human dietary supplement and dietary ingredient. Hawaiian Spirulina Pacifica is a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Its products are sold as consumer-packaged goods. |
Financial Overview |
For the nine months ended 31 December 2023, CYANOTECH CORP revenues decreased 4% to $17.1M. Net loss increased 59% to $3.2M. Revenues reflect Spirulina bulk segment decrease of 64% to $1M, Contract extraction revenue segment decrease of 51% to $258K. Higher net loss reflects Sales/Marketing increase of 21% to $4M (expense), Interest expense increase of 49% to $495K (expense). |
Employees: | 86 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8.17M as of Dec 31, 2023 |
Annual revenue (TTM): | $22.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.32M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.62M as of Dec 31, 2023 |
Free cash flow (TTM): | -$0.55M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $6.15M as of Dec 31, 2023 |
Shares outstanding: | 6,941,763 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |